Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. IBM
5. ACN
6. NVDA
7. PRIM
8. META
9. SPY
10. TSLA

Go back to Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

William Blair Downgrades Apellis Pharmaceuticals (APLS) to Market Perform

March 31, 2026 11:55 AM EDT

William Blair analyst Lachlan Hanbury-Brown downgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Apellis Pharmaceuticals click here. For more ratings news on Apellis Pharmaceuticals click here.

Shares of Apellis Pharmaceuticals closed at $17.09 yesterday.

... More